PO.TB04.03 · 肿瘤生物学
一种保留肿瘤微环境以指导个体化免疫治疗的新型肉瘤类肿瘤(tumoroid)平台
A novel sarcoma tumoroid platform preserving the tumor microenvironment to guide personalized immunotherapy
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
肉瘤是罕见的、侵袭性的间叶源性癌症,拥有80余种亚型。尽管其仅占成人癌症的一小部分,但肉瘤占儿童实体瘤的20%以上,且晚期患者预后不佳。临床前建模仍具挑战性:传统2D培养无法保留肿瘤微环境(TME),而常规3D类器官平台依赖酶解消化,这会破坏维持TME完整性所必需的细胞间相互作用。患者来源异种移植物虽更具代表性,但成本高且通量低。为解决这些局限,本研究旨在开发可重复的3D肉瘤类肿瘤,作为一个保留TME、用于功能研究和治疗测试的转化平台。
将新鲜切除的肉瘤标本在不进行酶解消化的情况下机械切成小碎片,从而在每个碎片中保留TME,并在悬浮或基质包埋条件下培养。跨肉瘤亚型评估了培养基配方和生长因子组合以优化培养效果。使用明场显微镜、定量面积分析和alamarBlue活力检测,对类肿瘤的形成和生长进行了14天的监测。通过苏木精-伊红(H&E)染色和免疫组织化学(IHC)评估结构完整性和TME保留情况。使用标准化疗药物(包括多柔比星和甲氨蝶呤)进行细胞毒性反应检测,在5天治疗期内评估3D培养中的药物敏感性。
所建立的类肿瘤在14天内保持一致的3D形态和活力,其中Mammocult培养基加生长因子支持最强的增殖。定量生长分析显示类肿瘤面积和代谢活性逐渐增加,表明在优化条件下稳定扩增。H&E染色证实骨肉瘤、去分化脂肪肉瘤和软骨肉瘤在10天以上保留了肿瘤细胞、间质和组织学结构。CD45的IHC染色证实培养物中存在免疫和间质细胞群,表明保留了天然TME。使用甲氨蝶呤和多柔比星进行的化疗测试通过H&E和活/死染色揭示出细胞毒性效应,验证了该模型的反应性和功能相关性。
这些发现表明,机械解离的肉瘤组织可生成具有活力、能代表亚型的类肿瘤,同时保留关键的TME特征。未来工作将聚焦于拓展治疗测试、整合免疫共培养系统以更好地再现肉瘤TME,并应用空间转录组学和单细胞RNA测序以揭示细胞异质性,指导肉瘤患者的精准肿瘤学。
查看英文原文 English abstract
Sarcomas are rare, aggressive mesenchymal cancers with over 80 subtypes. Although they represent a small fraction of adult cancers, sarcomas comprise over 20% of pediatric solid tumors and carry poor outcomes for patients with advanced disease. Preclinical modeling remains challenging: traditional 2D cultures fail to preserve the tumor microenvironment (TME), while conventional 3D organoid platforms rely on enzymatic dissociation, which disrupts cellular interactions essential for TME integrity. Patient-derived xenografts, though more representative, are costly and low-throughput. To address these limitations, this study aims to develop reproducible 3D sarcoma tumoroids as a translational platform for functional studies and therapeutic testing that preserves the TME.
Freshly resected sarcoma specimens were mechanically cut into small fragments without enzymatic dissociation, preserving the TME in each fragment, and cultured in suspension or matrix-embedded conditions. Media formulations and growth factor combinations were evaluated across sarcoma subtypes to optimize culture performance. Tumoroid formation and growth were monitored for 14 days using brightfield microscopy, quantitative area analysis, and alamarBlue viability assay. Structural integrity and TME preservation were assessed by hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC). Cytotoxic response assays were performed using standard chemotherapeutic agents, including doxorubicin and methotrexate, to evaluate drug sensitivity in 3D culture over a 5-day treatment period.
Established tumoroids maintained consistent 3D morphology and viability over 14 days, with Mammocult medium plus growth factors supporting the strongest proliferation. Quantitative growth analysis showed a progressive increase in tumoroid area and metabolic activity, indicating stable expansion under optimized conditions. H&E staining confirmed retention of tumor cells, stroma, and histologic architecture across osteosarcoma, dedifferentiated liposarcoma, and chondrosarcoma for over 10 days. IHC staining for CD45 confirmed the presence of immune and stromal cell populations within the cultures, indicating preservation of the native TME. Chemotherapeutic testing using methotrexate and doxorubicin revealed cytotoxic effects through H&E and Live/Dead staining, validating the model's responsiveness and functional relevance.
These findings demonstrate that mechanically dissociated sarcoma tissues can generate viable, subtype-representative tumoroids while maintaining key TME features. Future efforts will focus on expanding therapeutic testing, integrating immune co-culture systems to better recapitulate the sarcoma TME, and applying spatial transcriptomics and single-cell RNA sequencing to uncover cellular heterogeneity and guide precision oncology for sarcoma patients.
利益披露 Disclosure
T. Ezzat, None..
N. Ruppert, None..
D. G. Cho, None..
T. E. Miller, None..
Z. D. Burke, None.